These data indicate that vertical inhibition of proximal EGFR signaling with the combination of osimertinib and a SOS1 inhibitor may be the most the most effective therapeutic combination to treat EGFR-mutated NSCLC. The gene discussed is SOS1; the disease is non-small cell lung carcinoma.